Recursion Pharmaceuticals, Inc. (RXRX)
3.63
+0.19
(+5.52%)
USD |
NASDAQ |
Sep 04, 16:00
3.645
+0.02
(+0.41%)
After-Hours: 20:00
Recursion Pharmaceuticals Research and Development Expense (Quarterly) : 77.91M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 77.91M |
| March 31, 2026 | 75.20M |
| December 31, 2025 | 83.34M |
| September 30, 2025 | 107.66M |
| June 30, 2025 | 116.34M |
| March 31, 2025 | 117.93M |
| December 31, 2024 | 91.44M |
| September 30, 2024 | 70.50M |
| June 30, 2024 | 70.03M |
| March 31, 2024 | 64.16M |
| December 31, 2023 | 66.08M |
| September 30, 2023 | 66.61M |
| June 30, 2023 | 53.46M |
| Date | Value |
|---|---|
| March 31, 2023 | 46.52M |
| December 31, 2022 | 43.83M |
| September 30, 2022 | 40.76M |
| June 30, 2022 | 38.36M |
| March 31, 2022 | 32.36M |
| December 31, 2021 | 48.22M |
| September 30, 2021 | 33.17M |
| June 30, 2021 | 29.55M |
| March 31, 2021 | 24.03M |
| December 31, 2020 | 20.70M |
| September 30, 2020 | 16.48M |
| June 30, 2020 | 13.24M |
| March 31, 2020 | 12.84M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Twist Bioscience Corp. | 18.02M |
| Absci Corp. | 22.62M |
| Novavax, Inc. | 67.79M |
| Editas Medicine, Inc. | 19.76M |
| Halozyme Therapeutics, Inc. | 27.66M |